Sansure Biotech Inc. (688289.SS)
CNY 19.16
(0.9%)
CNY 19.16
(0.9%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 620.65 Million CNY | -83.65% |
| 2022 | 3.79 Billion CNY | 17.29% |
| 2021 | 3.23 Billion CNY | -14.7% |
| 2020 | 3.79 Billion CNY | 1493.17% |
| 2019 | 238.07 Million CNY | 34.2% |
| 2018 | 177.4 Million CNY | 58.56% |
| 2017 | 111.87 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 314.68 Million CNY | 23.38% |
| 2024 Q2 | 204.54 Million CNY | -35.0% |
| 2024 Q3 | 246.3 Million CNY | 20.42% |
| 2023 Q2 | 153.76 Million CNY | 16.77% |
| 2023 FY | 620.65 Million CNY | -83.65% |
| 2023 Q1 | 131.68 Million CNY | -90.46% |
| 2023 Q3 | 149.31 Million CNY | -2.89% |
| 2023 Q4 | 255.04 Million CNY | 70.81% |
| 2022 Q4 | 1.38 Billion CNY | 72.04% |
| 2022 Q2 | 709.48 Million CNY | -21.41% |
| 2022 Q1 | 902.72 Million CNY | 13.67% |
| 2022 Q3 | 802.36 Million CNY | 13.09% |
| 2022 FY | 3.79 Billion CNY | 17.29% |
| 2021 Q1 | 858.38 Million CNY | 3.45% |
| 2021 Q2 | 670.15 Million CNY | -21.93% |
| 2021 FY | 3.23 Billion CNY | -14.7% |
| 2021 Q4 | 794.19 Million CNY | -12.99% |
| 2021 Q3 | 912.76 Million CNY | 36.2% |
| 2020 FY | 3.79 Billion CNY | 1493.17% |
| 2020 Q4 | 829.77 Million CNY | -31.88% |
| 2020 Q1 | 324 Million CNY | 298.75% |
| 2020 Q2 | 1.42 Billion CNY | 338.6% |
| 2020 Q3 | 1.21 Billion CNY | -14.28% |
| 2019 FY | 238.07 Million CNY | 34.2% |
| 2019 Q3 | 55.25 Million CNY | 1.09% |
| 2019 Q2 | 54.66 Million CNY | 16.54% |
| 2019 Q1 | 46.9 Million CNY | 0.0% |
| 2019 Q4 | 81.25 Million CNY | 47.05% |
| 2018 FY | 177.4 Million CNY | 58.56% |
| 2017 FY | 111.87 Million CNY | 0.0% |